Drug-RNA footprinting.
RNase I and RNase T1 can be used to obtain high-quality footprinting information for paromomycin binding to a 176-mer RNA from the packaging region of HIV-1 (LAI). Controls and scanning procedures are necessary for quantitation of autoradiographic data, so that footprinting plots showing cutting behavior as a function of drug concentration can be used to identify binding sites and regions of altered structure on the 176-mer. From the RNase I footprinting results the primary paromomycin binding sites on the 176-mer are on the main stem and on the stem of SL1, but noncontiguous sequences may be involved in the same binding event. Strong enhancements in cleavage with added drug are also observed, indicating drug-induced structural changes. Drug binding may cause linker regions between stem-loops of the 176-mer to change structure, possibly providing a site or sites for additional drug binding. Because drug binding changes the structure of the packaging region, which may alter its function, paromomycin analogs with enhanced specificity for HIV psi RNA have potential as a new class of agent for treating AIDS.
McPike
M P
MP
Department of Chemistry, Center for Science and Technology, Syracuse University, Syracuse, New York 13244, USA.
Goodisman
J
J
Dabrowiak
J C
JC
D001483:Base Sequence; D018983:DNA Footprinting / Q000379:methods*; D017931:DNA Primers / Q000235:genetics; D015497:HIV-1 / Q000737:chemistry / Q000235:genetics; D008024:Ligands; D008969:Molecular Sequence Data; D009690:Nucleic Acid Conformation; D010303:Paromomycin; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D012313:RNA / Q000138:chemical synthesis / Q000737:chemistry* / Q000235:genetics; D012367:RNA, Viral / Q000737:chemistry / Q000235:genetics
D017931:DNA Primers; D008024:Ligands; D004364:Pharmaceutical Preparations; D012367:RNA, Viral; D010303:Paromomycin; D012313:RNA